Outlook Therapeutics (OTLK) Operating Expenses: 2015-2024
Historic Operating Expenses for Outlook Therapeutics (OTLK) over the last 10 years, with Sep 2024 value amounting to $71.7 million.
- Outlook Therapeutics' Operating Expenses fell 46.00% to $10.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $36.8 million, marking a year-over-year decrease of 17.11%. This contributed to the annual value of $71.7 million for FY2024, which is 34.97% up from last year.
- According to the latest figures from FY2024, Outlook Therapeutics' Operating Expenses is $71.7 million, which was up 34.97% from $53.1 million recorded in FY2023.
- Over the past 5 years, Outlook Therapeutics' Operating Expenses peaked at $71.7 million during FY2024, and registered a low of $36.8 million during FY2020.
- In the last 3 years, Outlook Therapeutics' Operating Expenses had a median value of $63.1 million in 2022 and averaged $62.6 million.
- As far as peak fluctuations go, Outlook Therapeutics' Operating Expenses fell by 17.11% in 2020, and later skyrocketed by 40.41% in 2021.
- Yearly analysis of 5 years shows Outlook Therapeutics' Operating Expenses stood at $36.8 million in 2020, then soared by 40.41% to $51.7 million in 2021, then climbed by 21.93% to $63.1 million in 2022, then declined by 15.77% to $53.1 million in 2023, then skyrocketed by 34.97% to $71.7 million in 2024.